Propanc Biopharma, Inc.

As of March 31, 2026, Propanc Biopharma, Inc. carries a market capitalization of 2.32M, placing it among publicly traded companies globally. Its enterprise value stands at 3.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Propanc Biopharma, Inc. has 874,371.00 shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Propanc Biopharma, Inc. maintains a current ratio of 2.37, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.30, indicating elevated leverage, while an interest coverage ratio of -27.92 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Propanc Biopharma, Inc. posted a negative return on equity (ROE) of -131.52, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -99.62, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Propanc Biopharma, Inc.'s stock has declined approximately 99.21% over the past 52 weeks. The 50-day moving average sits at 0.78, while the 200-day moving average is 2.68.

Over the twelve months ended March 31, 2026, Propanc Biopharma, Inc. generated - - in revenue and converted that into -18.36M in net income, yielding earnings per share of -30.74. EBITDA reached -18.35M, while operating income came in at -18.37M.

As of March 31, 2026, Propanc Biopharma, Inc. holds 443,702.00 in cash and equivalents against 573,873.00 in total debt, resulting in a net debt position of 76,580.00. Total book value stands at 9.83M, with working capital of 4.75M providing operational flexibility.

Propanc Biopharma, Inc. produced -4.11M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -4,912.00 in capital expenditures, free cash flow totaled -4.11M - equivalent to -6.89 per share.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -259.83: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -193.40, meaning Propanc Biopharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Propanc Biopharma, Inc.'s most recent stock split took place on May 18, 2026 with a 25:1 split ratio.

As of March 31, 2026, Propanc Biopharma, Inc. has an Altman Z-Score of -17.19, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.